Trials / Completed
CompletedNCT00240331
AURORA: Crestor 10mg Versus Placebo in Subjects With End-stage Renal Disease (ESRD)
A Study to Evaluate the Use of Rosuvastatin in Subjects On Regular Haemodialysis: an Assessment of Survival and Cardiovascular Events (AURORA). A Double Blind, Randomised, Phase 3b, Parallel-group Study to Compare the Effects of Rosuvastatin With Placebo on Assessment of Survival & Cardiovascular Events When Given to Subjects With End-stage Renal Failure on Chronic Haemodialysis Treatment
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 2,776 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 50 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to see if rosuvastatin helps to reduce the number of heart attacks, strokes and cardiovascular deaths in patients undergoing haemodialysis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 10mg Rosuvastatin | |
| DRUG | Placebo |
Timeline
- Start date
- 2003-01-01
- Primary completion
- 2008-10-01
- Completion
- 2008-10-01
- First posted
- 2005-10-18
- Last updated
- 2011-05-19
- Results posted
- 2009-11-04
Locations
239 sites across 25 countries: Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Mexico, Netherlands, Norway, Poland, South Korea, Sweden, Switzerland, Turkey (Türkiye), United Kingdom
Source: ClinicalTrials.gov record NCT00240331. Inclusion in this directory is not an endorsement.